Covid-19 roundup: With efficacy data in hand, BioNTech talks pricing; Brazil halts Sinovac trial following patient death
On the heels of becoming the first to release Phase III efficacy data for the Covid-19 vaccine it developed with Pfizer, BioNTech is now talking pricing.
BioNTech CSO Ryan Richardson said at a Financial Times virtual event that the company is aiming to set a price point below “typical market rate” for its two-shot vaccine, per Reuters. The firm also expects the price will be different depending on the country or region in which it’s sold, though Richardson did not elaborate.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters